Pretreatment Neutrophil-to-Lymphocyte Ratio and Lactate Dehydrogenase Predict the Prognosis of Metastatic Cervical Cancer Treated with Combination Immunotherapy

Table 3

Univariate and multivariate analyses of progression-free survival in patients with metastatic cervical cancer treated with combination immunotherapy.

Variables	Univariate		Multivariate
	HR (95% CI)		HR (95% CI)
Age (<50 vs. ≥50 years)	1.198 (0.658–2.184)	0.554
Histology (squamous cell carcinoma vs. adenocarcinoma)	2.448 (1.291–4.645)	0.006	3.258 (1.652–6.422)	0.001
Disease status (local recurrence vs. distant metastasis)	0.581 (0.320–1.053)	0.074
Prior radiotherapy (yes vs. no)	0.611 (0.258–1.447)	0.263
Line of immunotherapy (<3 vs. ≥3)	1.592 (0.865–2.930)	0.135
NLR (<5.33 vs. ≥5.33)	2.140 (1.005–4.342)	0.035	2.401 (1.151–5.009)	0.020
PLR (<297.92 vs. ≥297.92)	1.614 (0.814–3.200)	0.171
MLR (<0.29 vs. ≥0.29)	2.528 (0.993–6.431)	0.052
SCC-Ag (<2.85 vs. ≥2.85)	1.218 (0.672–2.208)	0.516
AGR (<1.80 vs. ≥1.80)	1.122 (0.537–2.345)	0.759
LDH (<195.00 vs. ≥195.00)	2.073 (1.090–3.942)	0.026	1.987 (1.029–3.835)	0.041
ALP (<87.50 vs. ≥87.50)	0.973 (0.538–1.762)	0.929

Abbreviations: AGR, albumin-to-globulin ratio; ALP, alkaline phosphatase; CI, confidence interval; HR, hazard ratio; LDH, lactate dehydrogenase; MLR, monocyte-to-lymphocyte ratio; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; SCC-Ag, squamous cell carcinoma-associated antigen.